Sanofi Faces Charges Over Valproate Birth Defects
French Regulator Planning More Preventive Measures
In a case that has parallels with that of Servier’s diabetes drug Mediator, Sanofi has been indicted over its alleged lack of transparency over the birth defects associated with use of its valproate drug in pregnant women.
